The Board of Directors of the Company at their meeting held today approved the Standalone Unaudited Financial Results of the Company for the third quarter and nine months ended on 31st ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
BDH Industries reported strong Q3 FY26 results with revenue from operations of ₹2,933.89 lakhs, up about 81% from ₹1,619.63 lakhs in Q3 FY25. Profit after tax rose to ₹348.90 lakhs (≈24% YoY growth) from ₹280.90 lakhs. For the nine months ended December 2025, revenue grew to ₹6,692.23 lakhs (≈37% YoY) and PAT rose to ₹793.47 lakhs from ₹678.46 lakhs. Q3 EPS stood at ₹6.06 vs ₹4.88 a year ago. The Pharmaceuticals segment contributed nearly all of the revenue (~99.5%), with Renewable Energy remaining a small contributor. The statutory auditor CLB & Associates issued an unmodified limited review report.
Strong top-line growth driven by the core Pharmaceuticals business is a positive for shareholders, though margins appear to have compressed versus the year-ago quarter, likely due to higher raw material costs. The clean, unqualified auditor review supports confidence in the numbers.